Prostate cancer in 2017

Advances in imaging

In the past year, the results of three studies in the field of prostate cancer imaging — the prostate MR imaging study (PROMIS), an analysis of the cost-effectiveness of various diagnostic strategies based on PROMIS data, and a retrospective analysis of a prostate-specific membrane antigen (PSMA)-directed PET radiopharmaceutical — have been published that could have lasting effects on clinical practice.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Ahmed, H. U. et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389, 815–822 (2017).

    Article  Google Scholar 

  2. 2

    Faria, R. et al. Optimising the diagnosis of prostate cancer in the era of multiparametric magnetic resonance imaging: a cost-effectiveness analysis based on the prostate MR imaging study (PROMIS). Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2017.08.018 (2017).

  3. 3

    Afshar-Oromieh, A. et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur. J. Nucl. Med. Mol. Imaging 44, 1258–1268 (2017).

    Article  Google Scholar 

  4. 4

    Moldovan, P. C. et al. What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur. Urol. 72, 250–266 (2017).

    Article  Google Scholar 

  5. 5

    Delongchamps, N. B. et al. Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies. J. Urol. 189, 493–499 (2013).

    Article  Google Scholar 

  6. 6

    Puech, P. et al. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy — prospective multicenter study. Radiology 268, 461–469 (2013).

    Article  Google Scholar 

  7. 7

    Gillessen, S. et al. Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2017.06.002 (2017).

  8. 8

    Vargas, H. A. et al. Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1 ng/ml following prostatectomy: how much information can conventional imaging provide? Urol. Oncol. 34, 482.e5–482.e10 (2016).

    Article  Google Scholar 

  9. 9

    Nanni, C. et al. 18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial. Eur. J. Nucl. Med. Mol. Imaging 43, 1601–1610 (2016).

    CAS  Article  Google Scholar 

  10. 10

    von Eyben, F. E. et al. 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis. Eur. Urol. Focus http://dx.doi.org/10.1016/j.euf.2016.11.002 (2016).

Download references

Acknowledgements

The authors thank Ada Muellner, MS, of Memorial Sloan Kettering Cancer Center, who helped edit the manuscript before submission.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Andreas G. Wibmer.

Ethics declarations

Competing interests

A.G.W. has received support from the Peter Michael Foundation. H.H. serves on the Board of Directors of Ion Beam Application (IBA), a role for which she receives annual compensation.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wibmer, A., Vargas, H. & Hricak, H. Advances in imaging. Nat Rev Urol 15, 81–82 (2018). https://doi.org/10.1038/nrurol.2017.210

Download citation

Search

Quick links

Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing